CA Stock MarketDetailed Quotes
RVX Resverlogix Corp
- 0.055
- -0.005-8.33%
15min DelayMarket Closed Dec 13 16:00 ET
15.44MMarket Cap-1.02P/E (TTM)
0.055High0.055Low53.30KVolume0.055Open0.060Pre Close2.93KTurnover0.09552wk High0.03%Turnover Ratio280.65MShares0.04052wk Low-0.054EPS TTM10.36MFloat Cap29.500Historical HighLossP/E (Static)188.32MShs Float0.040Historical Low-0.08EPS LYR0.00%Amplitude--Dividend TTM-0.13P/B1Lot Size--Div YieldTTM
About Resverlogix Corp Company
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Company Profile
SymbolRVX
Company NameResverlogix Corp
Founded2000
MarketTSE
Employees18
Fiscal Year Ends12-31
Address4820 Richard Road South West Suite 300
CityCalgary
CountryCAN
Zip CodeT3E 6L1
Phone+1 403 254-9252
Websitehttps://www.resverlogix.com
Company Executives
- Name
- Position
- Salary
- Donald J. McCaffrey
- Chairman of the Board, President, Secretary and Chief Executive Officer
- --
- A. Brad Cann, C.A.,C.P.A.
- Chief Financial Officer
- --
- Dr. Ewelina Kulikowski, PhD
- Chief Scientific Officer
- --
- Dr. Michael Sweeney,M.D.
- Senior Vice President, Clinical Development
- --
- Siu Lun To
- Independent Director
- --
- Kelly McNeill, B.Comm.,C.A.
- Independent Director
- --
- Kenneth J. Zuerblis
- Independent Director
- --
Heat List
CA
Overall
Symbol
Price
% Chg
No Data